- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
A study in the December issue of the International Journal of Antimicrobial Agents, examined the benefits of early treatment with a triple drug therapy. Researchers examined data from nearly 150 patients treated for five days with a combination of low-dose hydroxychloroquine (HCQ), azithromycin, and zinc between 18 March and 14 May. All of the cases examined were in New York State, USA. This data was compared to patients from the same community not treated with this triple drug cocktail. The results showed a reduced rate of hospitalisation and decreased mortality rates in those who received the treatment.
Researchers noted that in previous studies involving HCQ and the use of azithromycin, the medications were always administered at least 6 days after onset of symptoms. These previous studies had inconclusive results. In this study, the average time to consultation with a healthcare provider was 4 days. The study was limited in both size and diversity of population studied. The US Food and Drug Administration currently recommends against the use of HCQ due to the risk of heart rhythm problems. The drug azithromycin is also known to cause heart rhythm problems and has a black box warning to this effect in the US.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
